KSB301: KSB discontinued development of KSB301, which did not show superiority to treatment with the NSAID diclofenac in a placebo-controlled Phase IIb trial in

KS Biomedix Holdings Plc (LSE:KSB), Guilford, U.K. Product: KSB301 (CB-2431) Business: Musculoskeletal, Autoimmune/Inflammation Therapeutic category: Disease modifying antirheumatic drug (DMARD) Targe...